A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer

References

• Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Res 2013; 15:209; PMID:23905624; http://dx.doi.org/10.1186/bcr3435
   PubMedGoogle Scholar
• Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta 2013; 1832:1070-8; PMID:23123598; http://dx.doi.org/10.1016/j.bbadis.2012.10.013
   PubMed Web of Science ®Google Scholar
• Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL, Vizoso FJ. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 2007; 97:957-63; PMID:17848954; http://dx.doi.org/10.1038/sj.bjc.6603935
   PubMed Web of Science ®Google Scholar
• Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO, Vizoso F, Perez-Fernandez R. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest 2010; 120:4289-302; PMID:21060149; http://dx.doi.org/10.1172/JCI42015
   PubMedGoogle Scholar
• Gonzalez LO, Corte MD, Junquera S, Gonzalez-Fernandez R, del Casar JM, Garcia C, Andicoechea A, Vazquez J, Perez-Fernandez R, Vizoso FJ. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol 2009; 40:1224-33; PMID:19439346; http://dx.doi.org/10.1016/j.humpath.2008.12.022
   PubMedGoogle Scholar
• Del Casar JM, Gonzalez-Reyes S, Gonzalez LO, Gonzalez JM, Junquera S, Bongera M, Garcia MF, Andicoechea A, Serra C, Vizoso FJ. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol 2010; 136:811-9; PMID:19916023; http://dx.doi.org/10.1007/s00432-009-0721-2
   PubMedGoogle Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-49; PMID:10694567
   PubMed Web of Science ®Google Scholar
• Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114:111-8; PMID:11112695
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516; PMID:11687497; http://dx.doi.org/10.1146/annurev.cellbio.17.1.463
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74; PMID:11990853; http://dx.doi.org/10.1038/nrc745
   PubMed Web of Science ®Google Scholar
• Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin ; MMP-7 expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001; 3:459-68; PMID:11774028; http://dx.doi.org/10.1038/sj.neo.7900190
   PubMedGoogle Scholar
• Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103:1237-41; PMID:10225966; http://dx.doi.org/10.1172/JCI6870
   PubMed Web of Science ®Google Scholar
• Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 161:6845-52; PMID:9862716
   PubMed Web of Science ®Google Scholar
• Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326:1216-9; PMID:19965464; http://dx.doi.org/10.1126/science.1176009
   PubMed Web of Science ®Google Scholar
• Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287-97; PMID:19738110; http://dx.doi.org/10.1200/JCO.2009.23.5556
   PubMed Web of Science ®Google Scholar
• Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21:2245-52; PMID:11948407; http://dx.doi.org/10.1038/sj.onc.1205291
   PubMed Web of Science ®Google Scholar
• Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158:1207-15; PMID:11290537; http://dx.doi.org/10.1016/S0002-9440(10)64070-9
   PubMedGoogle Scholar
• Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214:357-67; PMID:18044827; http://dx.doi.org/10.1002/path.2278
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-27; PMID:18438415; http://dx.doi.org/10.1038/nm1764
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
   PubMed Web of Science ®Google Scholar
• Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678-87; PMID:21846823; http://dx.doi.org/10.1158/0008-5472.CAN-11-0431
   PubMed Web of Science ®Google Scholar
• Ahn S, Cho J, Sung J, Lee JE, Nam SJ, Kim KM, Cho EY. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol 2012; 33:1573-80; PMID:22581521; http://dx.doi.org/10.1007/s13277-012-0411-6
   PubMedGoogle Scholar
• Min KW, Kim DH, Do SI, Pyo JS, Kim K, Chae SW, Sohn JH, Oh YH, Kim HJ, Choi SH, et al. Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblast-like cells adjacent to invasive ductal carcinoma of the breast. Ann Surg Oncol 2013; 20 Suppl 3:S433-42; PMID:23115007; http://dx.doi.org/10.1245/s10434-012-2734-3
   PubMed Web of Science ®Google Scholar
• Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 2013; 4:66-83; PMID:23386906; http://dx.doi.org/10.7150/jca.5112
   PubMed Web of Science ®Google Scholar
• Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'–more than meets the eye. Trends Mol Med 2013; 19:447-53; PMID:23769623; http://dx.doi.org/10.1016/j.molmed.2013.05.004
   PubMed Web of Science ®Google Scholar
• Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer 2013; 20:1-12; PMID:23111755; http://dx.doi.org/10.1530/ERC-12-0227
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Calorini L, Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 2011; 14:2361-71; PMID:21235356; http://dx.doi.org/10.1089/ars.2010.3727
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401; PMID:16572188; http://dx.doi.org/10.1038/nrc1877
   PubMed Web of Science ®Google Scholar
• Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32:303-15; PMID:23114846; http://dx.doi.org/10.1007/s10555-012-9415-3
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013; 85:1033-41; PMID:23376122; http://dx.doi.org/10.1016/j.bcp.2013.01.018
   PubMed Web of Science ®Google Scholar
• Rasanen K, Virtanen I, Salmenpera P, Grenman R, Vaheri A. Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS One 2009; 4:e6879; PMID:19721715; http://dx.doi.org/10.1371/journal.pone.0006879
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Spangeus A, Valila J, Sandstrom P, Borch K, Druid H, Falkmer S, Falkmer U, Messmer D, Larsson M. Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011; 13:664-75; PMID:21847358
   PubMedGoogle Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876
   PubMed Web of Science ®Google Scholar
• Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. Chemokines in tumor-associated angiogenesis. Biol Chem 2009; 390:1213-23; PMID:19804363; http://dx.doi.org/10.1515/BC.2009.144
   PubMed Web of Science ®Google Scholar
• Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010; 21:33-9; PMID:19896548; http://dx.doi.org/10.1016/j.semcdb.2009.10.010
   PubMed Web of Science ®Google Scholar
• Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 2010; 15:166-79; PMID:20036813; http://dx.doi.org/10.2741/3613
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324
   PubMed Web of Science ®Google Scholar
• Adams TE, Alpert S, Hanahan D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 1987; 325:223-8; PMID:3543686; http://dx.doi.org/10.1038/325223a0
   PubMed Web of Science ®Google Scholar
• Eiro N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas ML, del Casar JM, Gonzalez LO, Lopez-Muniz A, Vizoso FJ. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One 2012; 7:e52796; PMID:23300781; http://dx.doi.org/10.1371/journal.pone.0052796
   PubMedGoogle Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22; PMID:22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022
   PubMed Web of Science ®Google Scholar
• Gonzalez LO, Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez JM, Lamelas ML, Merino AM, Rodriguez E, Pidal I, del Casar JM, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 2010; 57:862-76; PMID:21166700; http://dx.doi.org/10.1111/j.1365-2559.2010.03723.x
   PubMedGoogle Scholar
• Eiro N, Gonzalez L, Gonzalez LO, Fernandez-Garcia B, Lamelas ML, Marin L, Gonzalez-Reyes S, del Casar JM, Vizoso FJ. Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One 2012; 7:e49047; PMID:23145063; http://dx.doi.org/10.1371/journal.pone.0049047
   PubMedGoogle Scholar
• Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32:355-7; PMID:12379854; http://dx.doi.org/10.1038/ng1013
   PubMed Web of Science ®Google Scholar
• Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357:2543-51; PMID:18094375; http://dx.doi.org/10.1056/NEJMoa071825
   PubMed Web of Science ®Google Scholar
• Hosein AN, Wu M, Arcand SL, Lavallee S, Hebert J, Tonin PN, Basik M. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 2010; 70:5770-7; PMID:20570891; http://dx.doi.org/10.1158/0008-5472.CAN-10-0673
   PubMed Web of Science ®Google Scholar
• Eiró N, Sendon-Lago J, Seoane S, Bermúdez MA, Lamelas ML, Garcia-Caballero T, Schneider J, Perez-Fernandez R, Vizoso FJ. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells. Oncotarget 2014; 5:10692-708; PMID:25296979
   PubMedGoogle Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8:98-101; PMID:2673568
   PubMed Web of Science ®Google Scholar
• Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96:903-11; PMID:17342087; http://dx.doi.org/10.1038/sj.bjc.6603666
   PubMed Web of Science ®Google Scholar
• Del Casar JM, Gonzalez LO, Alvarez E, Junquera S, Marin L, Gonzalez L, Bongera M, Vazquez J, Vizoso FJ. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009; 116:39-52; PMID:19241156; http://dx.doi.org/10.1007/s10549-009-0351-z
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11:155-68; PMID:9504686
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-74; PMID:15328174; http://dx.doi.org/10.1158/1078-0432.CCR-04-0220
   PubMed Web of Science ®Google Scholar